Install Free Gold Price Widget!
Install Free Gold Price Widget!
Install Free Gold Price Widget!
|
- Fosgonimeton - ALZFORUM
NDX-1017 is a brain-penetrant small molecule that activates signaling via the hepatocyte growth factor (HGF) MET receptor system (Moebius and Church, 2023) HGF promotes proliferation and survival of neurons, enhances hippocampal synaptic plasticity, and boosts learning and memory (Akimoto et al , 2004; Kato et al , 2012) NDX-1017 is being
- Long-Term Hydromethylthionine Treatment Is Associated with Delayed . . .
Bentham P, Staff RT, Schelter BO, Shiells H, Harrington CR, Wischik CM Long-Term Hydromethylthionine Treatment Is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-Symptomatic P301S MAPT Mutation Carrier
- Ceperognastat - ALZFORUM
Overview Name: Ceperognastat Synonyms: LY3372689 Chemical Name: N-[4-fluoro-5-[[2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Therapy Type: Small Molecule Target Type: Tau Condition(s): Alzheimer's Disease U S FDA Status: Alzheimer's Disease (Discontinued) Company: Eli Lilly Co
- At CTAD, Early Failures and Hints of Success, from Small Trials
In the SAD study, gamma power rose after a single dose of 20 mg or more NDX-1017, indicating target engagement The increase was dose-dependent and statistically significant in the 90 mg dose group, Moebius reported In the MAD study, 40 mg NDX-1017 increased gamma power on day four and day eight in all seven AD patients who received the drug
- APP23 - ALZFORUM
APP23 is a transgenic mouse model used to study Alzheimer's disease, expressing human amyloid precursor protein with the Swedish mutation
- Leqembi - ALZFORUM
Sponsor Clinical Trial 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
- Therapeutics Search - ALZFORUM
ATH-1017, NDX-1017: Alzheimer's Disease (Discontinued), Dementia with Lewy Bodies (Discontinued), Parkinson's Disease Dementia (Discontinued) Athira Pharma: Other: Small Molecule: FRM-0334: EVP-0334: Frontotemporal Dementia (Discontinued) FORUM Pharmaceuticals Inc Other: Small Molecule: G-CSF: Filgrastim: Alzheimer's Disease (Phase 2) Other
- Progranulin: A Mark of Worsening Alzheimer’s? | ALZFORUM
In late-onset AD, the progranulin profile looked somewhat different, as demonstrated by CSF from 1,017 people from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
|
|
|